Drug Database
EP

epirizole (epirizole / Mepirazol / Alcyde)

✓ Approved

Daiichi Sankyo Company Limited · Small Molecule · Small Molecule

What is epirizole?

epirizole is a small molecule developed by Daiichi Sankyo Company Limited. It is approved for therapeutic indications via unknown.

Drug Profile

Brand Namesepirizole, Mepirazol, Alcyde
CompanyDaiichi Sankyo Company Limited
Drug ClassSmall Molecule
RouteUnknown
StatusApproved

Therapeutic Indications

epirizole is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Hepatobiliary disordersHepatitis✓ Approved

Related Research Articles

PubMedThe Journal of organic chemistry2024-05-22

Ullmann-Type N-, S-, and O-Arylation Using a Well-Defined 7-Azaindole-N-oxide (7-AINO)-Based Copper(II) Catalyst: Scope and Application to Drug Synthesis.

Talukdar Vishal V, Mondal Krishanu K, Halder Pallabi P, Das Parthasarathi P

An air-stable, robust, and well-defined copper(II)-7-azaindole-N-oxide-based catalyst [Cu2II(7-AINO)4] (abbreviated as Cu(II)-7-AINO) has been demonstrated as an efficient catalyst for various Ullmann-type coupling reactions. This easily prepared and cost-effective catalyst facilitates the arylation and heteroarylation of diverse N-, S-, and O-nucleophiles, including azoles, aminoazoles, (hetero)arylthiols, and phenols. Notably, they also exhibit substantial compatibility with a wide range of functional groups. Furthermore, the catalyst demonstrates significant selectivity for -NH sites of aminoazoles and -SH sites of aminothiophenols over -NH2 sites in both cases, enhancing its versatility. Exploiting the catalyst's chemo- and regioselective properties, we have successfully demonstrated the applicability of our methodology in synthesizing various drug molecules. Specifically, Epirizole analogue, Nilotinib, and Vortioxetine were successfully synthesized using our protocol.

PubMedJournal of pharmaceutical sciences1985-11-01

Preparations of agglomerated crystals of polymorphic mixtures and a new complex of indomethacin-epirizole by the spherical crystallization technique.

Kawashima Y Y, Lin S Y SY, Ogawa M M, Handa T T et al.

Agglomerated crystals of indomethacin and epirizole were prepared by the spherical crystallization technique. The solvent used was ethanol-water-chloroform, ethyl acetate-water, or ethyl acetate-aqueous sodium chloride. From the ethanol-chloroform-water system, we obtained agglomerated crystals of a polymorphic mixture of the beta form of indomethacin (original form, gamma) and amorphous epirizole. When the mole percent of epirizole loaded into the system was less than 63 and 38% for the ethyl acetate-water and ethyl acetate-aqueous sodium chloride systems, respectively, the agglomerated crystals consisted of a polymorphic mixture of the alpha form of indomethacin and amorphous epirizole. When the respective mole percent of epirizole loaded was more than 65 and 43% in the aforementioned systems, a new complex of indomethacin-epirizole (molecular ratio equal to 2:1) was obtained. Recovery of complex from the drugs loaded in the ethyl acetate-aqueous sodium chloride system was higher than that in the ethyl acetate-water system, as a result of a salting-out effect. The solubility of indomethacin in the agglomerated complex in a solution of 30% aqueous ethanol and in disintegration test solution no. 2 (composition, 0.05 M KH2PO4 plus 0.0236 M, NaOH, pH 6.8), specified in the Japanese Pharmacopeia X (JPX), was higher than in the physical mixture (molecular ratio of indomethacin to epirizole equal to 2:1). In the ethanol solution, indomethacin was transformed into the gamma form during dissolution, and a decrease in solubility occurred. The process of dissolution of the tablet of the agglomerated complex was described by zero-order kinetics.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMedLa Clinica terapeutica1983-09-30

[Controlled research on the use of epirizole in the therapy of rheumatoid arthritis].

Gallo M M, La Montagna G G

Ask about epirizole